Items tagged with Treatment
RESIST-TB webinar: Combined use of delamanid and bedaquiline (post)
RESIST-TB will host a webinar about the current evidence and practices for the combined use of delamanid and bedaquiline for the treatment of multidrug-resistant TB (MDR-TB) on 5 April 2018.
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant TB (post)
SETTING
Study on drug-resistant TB patients in India: Elderly TB patients with diabetes suffer higher adverse effects from medications (post)
The International Conference on Harmonization considers older people a “special population as they differ from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics and greater vulnerability to adverse drug reactions”.
Bedaquiline and delamanid effective in multidrug-resistant TB (post)
Bedaquiline and delamanid were effective and safe for the treatment of multidrug-resistant tuberculosis (MDR-TB), according to the results of a study published in the European Respiratory Journal.
Smartphone app monitors on daily TB therapy (post)
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits.
Daily antituberculosis therapy superior for pulmonary TB in PLWH (post)
Worldwide, tuberculosis (TB) remains the leading cause of morbidity and mortality for patients living with HIV (PLWH). As of 2009, the World Health Organization (WHO) recommended daily antituberculosis therapy (ATT) for TB in PLWH, while the standard of care in India at the time was intermittent, or thrice-weekly, ATT in those patients.
Could a new universal TB regimen help end the TB pandemic? (post)
As tuberculosis (TB) is the world's most lethal infectious disease, there is an urgent need to improve the treatment of this bacterial infection. One approach under consideration is the institution of a universal or “pan-TB” regimen comprising new agents capable of treating multidrug-resistant (MDR) and even extensively drug-resistant (XDR) TB.
The remarkable story of hope: how attitudes to drug-resistant TB changed (post)
The informal settlement of Khayelitsha in Cape Town is the latest site of a multi country trial that aims to transform the treatment for drug-resistant tuberculosis (DR-TB).
No oral cabotegravir dose adjustment expected with rifabutin (post)
Coadministered rifabutin modestly lowered plasma levels of oral cabotegravir and left cabotegravir troughs above those that maintain viral suppression with a 10-mg oral dose [1]. Simulations will be done to estimate the impact of rifabutin on long-acting injected cabotegravir.
Real-time, web-based tool to revolutionise drug-resistant TB treatment (post)
Melbourne researchers have designed a computer-generated model that will allow clinicians to tailor effective therapies for individual patients with multidrug-resistant tuberculosis (MDRTB), and as a result, reduce drug resistance globally.
Page 39 of 108 · Total posts: 0
←First 38 39 40 Last→